Health Care [ 8/12 ] | Biotechnology [ 28/73 ]
NASDAQ | Common Stock
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 25 | -0.26 Decreased by -8.33% | -0.26 |
| Mar 20, 25 | -0.09 Increased by +80.00% | -0.21 Increased by +56.31% |
| Nov 12, 24 | -0.31 Decreased by -19.23% | -0.21 Decreased by -47.62% |
| Aug 8, 24 | -0.22 Increased by +15.38% | -0.19 Decreased by -15.79% |
| May 17, 24 | -0.24 Decreased by -4.35% | -0.05 Decreased by -380.00% |
| Mar 14, 24 | -0.45 Decreased by -95.65% | -0.25 Decreased by -80.00% |
| Nov 2, 23 | -0.26 Increased by +44.68% | -0.25 Decreased by -4.00% |
| Aug 3, 23 | -0.26 Increased by +43.48% | -0.22 Decreased by -18.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 8.98 M Decreased by -10.99% | -70.16 M Decreased by -33.16% | Decreased by -781.13% Decreased by -49.60% |
| Dec 31, 24 | 29.00 K Decreased by -98.37% | -27.61 M Increased by +64.23% | Decreased by -95.19 K% Decreased by -2.09 K% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -82.09 M Decreased by -79.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -58.27 M Decreased by -27.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 10.09 M Increased by +681.04% | -52.69 M Decreased by -32.35% | Decreased by -522.15% Increased by +83.05% |
| Dec 31, 23 | 1.77 M Decreased by -53.59% | -77.17 M Decreased by -186.34% | Decreased by -4.35 K% Decreased by -517.04% |
| Sep 30, 23 | 406.00 K Decreased by -82.86% | -45.85 M Decreased by -7.21% | Decreased by -11.29 K% Decreased by -525.55% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -45.55 M Decreased by -8.31% | Decreased by N/A% Decreased by N/A% |